# NCT03634982 (NCT03634982)

> Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

No report yet. It can be ordered.

- Drugs tested: RMC-4630
- Indication: relapsed/refractory solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03634982
- Phase: PHASE1
- Status: UNKNOWN
- Sponsor: Revolution Medicines, Inc.
- Conditions: Solid Tumors
- Interventions: RMC-4630
- Enrollment: 133
- Primary outcome: Number of participants with adverse events (AEs)
- Primary outcome: Number of participants with dose limiting toxicities (DLTs)

## Indexed commentary on NCT03634982 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03634982